XOMA focuses its antibody research and development on allosteric modulation, which offers opportunities for new classes of therapeutic antibodies to treat a wide range of human diseases. The company is developing its lead product, gevokizumab, with Servier through a global phase 3 program in non-infectious uveitis and ongoing proof-of-concept studies in other IL-1-mediated diseases. For more information, visit the company’s Web site: http://www.xoma.com
Let us hear your thoughts below: